<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

qz
UCB is snapping up U.S. autoimmune biotech Candid Therapeutics for $2.2 billion

The Belgian pharma company is paying $2 billion upfront for Candid's pipeline of T-cell engagers targeting autoimmune diseases [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

thenextweb
UCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune disease

The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseas [...]

Match Score: 171.64

thenextweb
Cambridge biotech STORM Therapeutics raises $56M

STC-15 is the world’s first RNA-modifying enzyme inhibitor to reach human trials. Phase 1 showed durable tumour regression across multiple sarcoma subtypes. The $56M Series C is backed entirely by e [...]

Match Score: 59.30

Destination
Viking Therapeutics closer to bringing its Ozempic competitor to market

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm.Read more... [...]

Match Score: 34.82

Destination
A revolutionary cancer treatment could transform autoimmune disease

Researchers are testing CAR T cell therapy as a way to reset the immune system. [...]

Match Score: 33.04

venturebeat
Cerebras stock nearly doubles on day one as AI chipmaker hits $100 billion — what it means for AI infrastructure

Cerebras Systems, the Silicon Valley chipmaker that built the world's largest commercial AI processor, erupted onto the Nasdaq on Wednesday, opening at $350 per share — nearly double its $185 I [...]

Match Score: 32.31

venturebeat
Anthropic says it hit a $30 billion revenue run rate after 'crazy' 80x growth

Dario Amodei is not the kind of CEO who talks loosely about numbers. The Anthropic co-founder and chief executive, a former VP of research at OpenAI with a PhD in computational neuroscience from Princ [...]

Match Score: 31.81

thenextweb
Danish biotech Cellugy wants to replace microplastics in cosmetics

Danish biotech Cellugy has raised €8.1mn in EU funding to accelerate production of a biodegradable material designed to replace microplastics in cosmetics. The grant, awarded under the EU’s LIFE P [...]

Match Score: 31.56

thenextweb
NATO’s VC fund backs biotech startup for first time

The NATO Innovation Fund (NIF) has made its first investment in a biotechnology startup. The alliance’s VC arm announced today that it’s co-leading a $35mn Series A round for UK-based Portal Biote [...]

Match Score: 31.56

thenextweb
Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top stage in 61 years

Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the r [...]

Match Score: 31.56